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Abstract: Lipid nanocarriers, such as niosomes, are considered attractive candidates for non-viral
gene delivery due to their suitable biocompatibility and high versatility. In this work, we studied the
influence of incorporating chloroquine in niosomes biophysical performance, as well as the effect
of non-ionic surfactant composition and protocol of incorporation in their biophysical performance.
An exhaustive comparative evaluation of three niosome formulations differing in these parameters
was performed, which included the analysis of their thermal stability, rheological behavior, mean
particle size, dispersity, zeta potential, morphology, membrane packing capacity, affinity to bind
DNA, ability to release and protect the genetic material, buffering capacity and ability to escape
from artificially synthesized lysosomes. Finally, in vitro biological studies were, also, performed in
order to determine the compatibility of the formulations with biological systems, their transfection
efficiency and transgene expression. Results revealed that the incorporation of chloroquine in
niosome formulations improved their biophysical properties and the transfection efficiency, while the
substitution of one of the non-ionic surfactants and the phase of addition resulted in less biophysical
variations. Of note, the present work provides several biophysical parameters and characterization
strategies that could be used as gold standard for gene therapy nanosystems evaluation.
Keywords: chloroquine; niosomes; gene delivery; biophysical properties; surfactants
1. Introduction
Gene therapy is based on the modification or control of gene expression in order to
treat a specific disease [1]. There are two main gene carrier systems, viral and non-viral
vectors, which provide genetic material protection and enhance cell internalization [2,3].
Non-viral vectors are usually based on different biocompatible nanoparticles, which rep-
resent a safer strategy than viruses and their elaboration process is easier and cheaper.
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Although in many occasions non-viral vectors are still unable to reach the high transfec-
tion levels of viral counterparts, continuous advances in the field bring us closer to this
goal [4–7]. In fact, currently some lipid nanoparticles are already commercialized for drug
and RNA delivery, such as Onivyde® [8] and Onpattro™ [9], among others. In addition,
during the ongoing pandemic caused by the severe acute respiratory syndrome coron-
avirus 2 (SARS-CoV-2) infection, two lipid nanoparticle-formulated mRNA vaccines have
also been developed [10]. However, to date, non-viral vectors have not reached clinical
practice for DNA delivery. To this end, it is essential the carefully design and selection of
biomaterials to develop efficient nanocarriers with high biophysical performance.
Non-viral vectors can be classified on a wide variety of nanosized materials, including
cationic lipids, polymers and carbon-based nanostructures [3,11]. Regarding cationic lipids,
niosomes, which can be defined as vesicular structures made of non-ionic surfactants [12],
have gained attention over liposomes due to their lower costs, longer stability and lower
toxicity [13–16]. Basically, cationic niosome formulations for gene delivery applications [17]
contain a cationic lipid, which forms complexes with the negatively charged DNA and pro-
motes the fusion with cell membranes [18], non-ionic surfactants to form stable emulsions
and prevent particle aggregations [7] and “helper” components to enhance the biophys-
ical properties [19]. Cationic lipids have three main functional domains: a hydrophilic
head-group which enhances electrostatic interactions with the DNA and can be formed by
quaternary ammoniums, amines, amino acids, lysine, guanidiniums and heterocycles [20], a
hydrophobic domain usually composed of two saturated/unsaturated aliphatic chains [21]
and a linker bond which influences in the stability, biodegradability, transfection efficiency
and cytotoxicity of the cationic lipid [22]. This linker bond usually contains an ester, ester
amide, carbamate, disulphide, urea or phosphate, among others [22]. Some cationic lipids
are commercially available, such as 1,2-di-O-octadecenyl-3-trimethylammonium propane
(DOTMA) [7] or 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) [23], while others
can be tailor-synthesized for specific applications. Regarding non-ionic surfactants, the
most commonly used are polysorbates (Tween®) [7], sorbitan fatty acid esters (Span®) [24]
and polyoxyethylene alkyl ethers (Brij®) [25]. The chemical structure of these surfactants in-
fluences on the final product as well as on their hydrophilic-lipophilic balance (HLB), which
determines the oil or water solubility. For instance, the surfactants with long alkyl chains
usually produce larger vesicles with more rigidity and less deformable membranes [7,26].
The role of the “helper” component is to increase the stability and the fluidity of the lipid
bilayer, and it works as an adjuvant of the transfection process since it enhances cellular
uptake and intracellular trafficking [19,27,28]. Until now, “helper” components used in
non-viral vectors are neutral lipids such as phosphatidylethanolamine (DOPE) [23], choles-
terol, squalane, squalene [19] and lycopene [29], but, recently, other compounds have also
been explored. In this sense, chloroquine has emerged as an interesting material for gene
delivery due to its ability to promote endosomal escape, which constitutes a key limiting
step in every transfection process [30]. Although some peptides—such as cell-penetrating
peptides (CPPs)—and viruses have also been used to that end, chloroquine presents higher
stability than CPPs and its use results less complexity compared to viruses as it is not a
biological agent. In addition, the lower cost and easier scale-up production of chloroquine
also contribute to increase its attractiveness as a promising material for gene delivery pur-
poses. In this work, we hypothesize that chloroquine not only promotes endosomal escape,
but it could also be involved in the modification of different biophysical parameters of the
nanoparticle formulations, which might have a direct impact on the transfection process.
Along with the components and their chemical structure, the final biophysical proper-
ties of the system also depend on the elaboration method and the molar ratios between the
nanocarrier components and the genetic cargo, which ultimately lead to different biological
behaviors of the nanocomplexes [18,31–33]. To elaborate niosomes, many procedures have
been described [15,34,35] being the oil in water (o/w) emulsion technique one of the most
widely used. In this method, two phases are involved, the aqueous and the organic one.
The niosome components are dissolved in the corresponding phase depending on their
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solubility and, after that, both phases are mixed by sonication to elaborate the emulsion.
Thereupon, the organic solvent is evaporated from the emulsion under magnetic agitation
which results in the formation of the vesicles suspended into the aqueous medium [34,36].
The solubility of the components is the main factor when choosing the phase in which they
will be dissolved: lipophilic and hydrophilic compounds are added in the organic or in the
aqueous phase, respectively. Besides, HLB value of non-ionic surfactants normally rules
for their addition to organic or aqueous phase: the lower value, the more lipophilic, and
the higher value, the more hydrophilic. Additionally, depending on the procedure, the
components could be added in different phases, especially the non-ionic surfactants due to
their amphiphilic character [35].
Considering all these issues, the aim of this study was to determine, on the one hand,
the influence of incorporating chloroquine in niosomes as a biophysical performance en-
hancer agent and, on the other hand, the effect of varying non-ionic surfactant components
and their phase of addition—aqueous or organic—on the biophysical performance of nio-
somes. For that purpose, three different niosomes, named as formulations 1, 2 and 3, were
developed. Formulations 1 and 2 differed in one of the two non-ionic surfactants and their
phase of addition and both contained chloroquine as a “helper” component. Formulation 3
was elaborated as formulation 1, and only differed in the “helper” component as it was
formulated without chloroquine. The three niosome formulations were prepared by the
o/w emulsion technique and were analyzed in terms of differential scanning calorimetry
and rheological properties. Niosomes were complexed with the reporter plasmid EGFP
(pEGFP) to obtain nioplexes at cationic lipid/DNA mass ratios 2/1, 5/1 and 10/1, in order
to characterize their mean particle size, dispersity, zeta potential and morphology. The
membrane packing capacity of nioplexes was also evaluated, as well as the affinity to bind
DNA, release it and protect it from enzymatic digestion. In addition, the buffering capacity
of the formulations and their endosomal escape ability were also studied. Finally, in vitro
biological studies were performed in order to determine the compatibility of the formula-
tions with biological systems as well as their transfection efficiency and the duration of
gene expression over time in human cystic fibrosis airway epithelial (CuFi-1) cells.
2. Materials and Methods
2.1. Preparation of Niosomes and Nioplexes
Two niosome formulations based on cationic lipid were elaborated using the oil-in-water
emulsion technique as previously described [18]. Both formulations 1 and 2 contained in
their organic phase 5 mg of the tailor-synthesized cationic lipid 2,3-di(tetradecyloxy)propan-
1-amine(hydrochloride salt) (DTPA) [37], dissolved in 1 mL of dichlorometane (DCM)
(PanReac, Barcelona, Spain). The organic phase of formulation 1 also contained 12.5 mg
of poloxamer 407 (Merck KGaA, Darmstadt, Germany) and 12.5 mg of polysorbate 80
(PanReac, Barcelona, Spain) as non-ionic surfactants. The aqueous phase of both formu-
lation 1 and 2 contained 2.5 mg of chloroquine (Merck KGaA, Darmstadt, Germany) as
“helper” component dissolved in 5 mL of distilled water. Furthermore, the aqueous phase
of formulation 2 also contained 12.5 mg of poloxamer 188 (BASF, Ludwigshafen, Germany)
and 12.5 mg of polysorbate 80 as non-ionic surfactants. Formulation 3 was prepared
as to formulation 1 protocol but with the avoidance of chloroquine. The emulsion was
obtained by mixing the organic and the aqueous phases by sonication (Branson Sonifier
250; Branson Ultrasonics Corporation, Danbury, CO, USA) for 30 s at 50 W. The organic
solvent was removed from the emulsion by evaporation under magnetic agitation for 1 h
at room temperature. The chemical structure of the components, the summary of each
formulation components and the general scheme of their disposition in a niosome are
represented in Figure 1.
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Figure 1. Structure and chemical components of niosomes. (A) Chemical structure and millimolar quantity of niosome
components. (B) Description of the components in each formulation. (C) General scheme of a niosome.
Nioplexes were elaborated by mixing an appropriate volume of DNA stock solution
(EGFP reporter plasmid or pEGFP) with different volumes of the niosome formulations
to obtain different cationic lipid/DNA mass ratios 2/1, 5/1 and 10/1. The mixture was
incubated for 30 min at room temperature to enhance electrostatic interactions between the
niosomes and the genetic material to form the nioplexes.
2.2. Plasmid Propagation
Escherichia coli DH5α was used to propagate the CMS-EGFP reporter plasmid (5.5 kb,
PlasmidFactory, Bielefeld, Germany), named as pEGFP. Then, according to manufacturer’s
instructions, the pEGFP was purified using the Qiagen endotoxin-free plasmid purification
Maxi-prep kit (Qiagen, Hilden, Germany). The final concentration of pEGFP was quantified
by measuring the absorbance at 260 nm using a SimpliNano™ device (GE Healthcare,
Buckinghamshire, UK).
2.3. Nano DSC Studies
The characterization of the thermostability of niosome formulations 1, 2 and 3 was per-
formed by differential scanning calorimetry (DSC) using a Nano DSC device
(TA Instruments, New Castle, DE, USA). Both in the reference and in the sample cells,
MilliQ® water was introduced in order to obtain a buffer line. Measurements of formula-
tions 1, 2 and 3 were performed with niosomes in the sample chamber at a concentration of
0.5 mg/mL, prior to degassing. The temperature range was from 4 ◦C to 100 ◦C for all the
samples and the scan rate was 1.0 ◦C/1 min. Results were collected and analyzed using
the DSC Run 4.6 and Launch Nano Analyze 3.11 software (TA instruments, New Castle,
DE, USA), respectively. The Nano DSC chambers were cleaned after each run with MilliQ®
water, 2% DECON™ 90 and methanol.
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2.4. Rheological Studies
The rheological behavior of niosomes based on formulations 1, 2 and 3 was conducted
using the Advanced Rheometer AR1000 equipment (TA instruments, New Castle, DE,
USA). A flat plate with 20 mm of diameter was used. The concentration of the niosome
formulations was 1 mg/mL and the GAP was settled at 1200 µm. The shear stress and
the viscosity data were obtained at shear rates from 10 to 1000 s−1 with 10 points per
decade. Data were collected and processed using the Rheology Advantage™ software
(TA instruments, New Castle, DE, USA).
2.5. Morphology, Size, Dispersity and Superficial Charge
The morphology of niosomes was determined by transmission electron microscopy
(TEM) as previously described [6]. The hydrodynamic diameter, which includes particle
size, reported as mean particle intensity, and dispersity (Ð) of niosomes and their corre-
sponding nioplexes was measured by dynamic light scattering (DLS), and the zeta potential
was measured by Lasser Doppler velocimetry (LDV) in a Zetasizer Nano ZS (Malvern
Instruments, Worcestershire, UK). To carry on the measurements, 50 µL of each sample
were diluted in 950 µL of 0.1 mM NaCl solution. The particle hydrodynamic diameter
was obtained by cumulative analysis. The Smoluchowski approximation supported the
calculation of the zeta potential from the electrophoretic mobility. All measurements were
carried out in triplicate.
2.6. Nioplexes Membrane Packing Studies
Lipid packing studies were carried out for niosomes based on formulations 1, 2 and 3
and their corresponding nioplexes with the lipophilic probe laurdan (6-Dodecanoyl-2-
Dimethylaminonaphthalene) (Fisher Scientific, Madrid, Spain). Laurdan was dissolved in
dimethyl sulfoxide (DMSO) to obtain a concentration of 200 µM (stock solution). The assay
was performed in a 96-well black plate. The concentration of laurdan fluorescent dye in
each well was 0.5 µM and formulations at room temperature were added at a concentration
of 0.25 mM. Then, 0.1 mM of NaCl was added to reach a final volume of 200 µL per well.
The plate was measured in the TECAN plate reader at an excitation wavelength of 340 nm
and the emission spectrum was measured from 400 to 500 nm, increasing 5 nm in each
measurement and considering the intensity values at 440 nm (I440) and 490 nm (I490). The
general polarization (GP) value was calculated as a relative measure for membrane order
using the following formula: GP = (I440 − I490)/(I440 + I490) [38]. GP values range from −1
(least ordered) to +1 (most ordered). As a blank, laurdan reagent in NaCl solution was
used. Each measurement was performed in triplicate.
2.7. ITC Studies
Isothermal titration calorimetry (ITC) was used to monitorize niosome-pEGFP inter-
actions for nioplexes formation using a MicroCal PEAQ-ITC microcalorimeter (Malvern
Instruments, Worcestershire, UK). The assays were carried out at 25 ◦C by stepwise in-
jections of niosome formulations (1 mg/mL DTPA) into the reaction cell loaded with
an aqueous solution of pEGFP (0.0166 mg/mL) at the following injection sequences:
1 × 0.4 µL; 8 × 1.7 µL; 9 × 2.5 µL (formulation 1) and 1 × 0.4 µL; 6 × 1 µL; 14 × 2.3 µL
(formulations 2 and 3). The injections were carried out automatically under 750 rpm stirring.
The heat contributed by niosome dilution in MilliQ® water was measured in separate runs
using the same injection sequence and subtracted from the total heat produced following
each injection prior to the data analysis. The full set of experiments was carried out with
the same preparation of pEGFP for the three formulations, and using the same dilution of
niosomes in the binding and dilution runs of each formulation, in order to minimize errors.
2.8. DNA Release from Niosomes and Protection Capacity
An agarose (Merck KGaA, Darmstadt, Germany) gel electrophoresis assay was devel-
oped to analyze the ability of the niosomes to protect and release the DNA from enzymatic
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digestion. For DNA release assay, 12 µL of 7% sodium dodecyl sulfate (SDS) (Merck KGaA,
Darmstadt, Germany) was added to the samples and incubated for 10 min at room temper-
ature. For DNA protection analysis, 2 µL of DNase I enzyme (Merck KGaA, Darmstadt,
Germany) was added to the samples and incubated for 30 min at 37 ◦C, then 12 µL of
7% SDS (Merck KGaA, Darmstadt, Germany) was added and incubated for 10 min at
room temperature. Before running the gel, 2 µL of loading buffer were added to all sam-
ples. Naked DNA was used as a control at each condition. The amount of DNA per well
was 200 ng in all cases. The agarose gel (0.8%) was immersed in a Tris-acetate-EDTA
buffer and exposed for 45 min to 100 V. Once running was stopped, DNA bands were
stained with GelRed™ (Biotium, Hayward, CA, USA) and images were obtained with a
ChemiDoc™ MP Imaging System and analyzed with ImageLab™ Software (Bio-Rad Labo-
ratories, Hercules, CA, USA).
2.9. Buffer Capacity Assay
Acid-base titration assay was performed to determine the buffer capacity of the
niosome formulations, as described previously [39]. Each sample, with 0.1 mg/mL of
cationic lipid, was prepared in 10 mL of 150 mM NaCl and adjusted to pH 10 with 0.1 M
NaOH. Then, the samples were titrated with 0.1 M HCl solution, added in 5 µL to 5 µL,
and pH values were measured by a Crison pH-Meter GLP21.
2.10. Vulnerability Assay of Complexes in the Late Endosome
Micelles based on phosphatidylserine (PS) were developed as an analogue of the
lysosomal compartment, as described previously [40,41]. PS was dissolved in chloroform
at 1.6 mM and, straightaway, the solvent was completely evaporated under magnetic
stirring. Dried sample was resuspended with phosphate buffer solution and a dispersion
was obtained by sonication. PS and the nioplexes were incubated for 1 h at a pEGFP/PS
mass ratio of 1/50. Naked DNA was used as control. Subsequently, the amount of the
released DNA from each complex was determined by agarose gel electrophoresis. Samples
(containing 200 ng of pEGFP each well) were loaded onto a 0.8% agarose gel and exposed for
30 min to 100 V. DNA bands staining was performed as aforementioned. The quantification
of DNA bands was obtained using ImageLab 4.0.1 software and the percentage of DNA
released was calculated applying the equation (1) where SC is supercoiled DNA:
% DNA released = (SC band/total DNA) × 100 (1)
2.11. Cell Culture and Transfection Assays
Human cystic fibrosis airway epithelial (CuFi-1) cells obtained from ATCC® CRL-4013™
were incubated at 37 ◦C and 5% CO2 atmosphere in collagen type IV (Merck KGaA,
Darmstadt, Germany) pre-treated flasks/plates and were split every 2–3 days to maintain
monolayer coverage. The cells were cultivated in bronchial epithelial growth medium—2 bullet
kit—(BEGM) (Lonza, Basel, Switzerland).
For transfection assays, cells were seeded in 24 well plates at a density of 1.6 × 105 cells
per well (for posterior flow cytometry analysis) or in 96 well plates at a density of
3 × 104 cells per well (for posterior kinetic analysis) and incubated overnight to achieve
70% of confluence at the time of transfection. The formation of nioplexes at 2/1, 5/1 and
10/1 cationic lipid/DNA mass ratios were performed in serum-free Opti-MEM transfection
medium (Gibco, San Diego, CA, USA). The growth medium was removed from the plate
and the cells were exposed to nioplexes (1.25 µg and 0.21 µg of pEGFP per well in 24-well
and 96-well plates, respectively) for 4 h in the incubator. After the incubation, nioplexes
were removed and fresh growth medium was added to the cells. As a negative control
for transfection, cells were not exposed to nioplexes but were incubated in Opti-MEM
for 4 h. As a positive control for transfection, Lipofectamine™ 2000 transfection reagent
(Invitrogen, Waltham, MA, USA) was used. Each condition was performed in triplicate.
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2.12. Analysis of EGFP Expression and Cell Viability
Transfection capacity and compatibility with biological systems of nioplexes 1, 2 and 3
were evaluated over 7 days both qualitatively and quantitatively, using the
Cytation™ 1 equipment (BioTek Instruments, Winooski, VT, USA). For quantitative analysis
of transfection efficiency and biocompatibility, the green fluorescence intensity and the cell
absorbance at 600 nm were measured every 24 h for li7 days. For qualitative analysis of
both parameters, brightfield and fluorescent images of cells were also acquired every 24 h for
7 days. Cells were kept alive for the whole experiment and incubated at 37 ◦C and 5% CO2 in
the Cytation™ 1 equipment, without retrieving or moving the plate between measurements.
Transfection efficiency and cell viability were further quantitatively evaluated 48 h
after the exposure to nioplexes by flow cytometry. Specifically, EGFP expression, cell viabil-
ity and mean fluorescence intensity (MFI) analysis were conducted using a FACSCalibur
system flow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Trans-
fected cells were washed with Dulbecco´s phosphate buffered saline (DPBS) with calcium
and magnesium (Lonza, Basel, Switzerland). Cells were detached using Trypsin/EDTA
0.25% (Gibco, San Diego, CA, USA) and, then, trypsin inhibitor (DPBS with 1% of fetal
bovine serum (Gibco, San Diego, CA, USA) was added. Cells were centrifuged at 1100 rpm
for 5 min and the resulting pellet was resuspended in culture medium and transferred to
specific flow cytometer tubes. In order to evaluate cell viability, propidium iodide (Merck
KGaA, Darmstadt, Germany) was added in each sample at 1:300 dilution. The fluorescent
signals were measured at 525 nm (FL1) and 650 nm (FL3) corresponding to EGFP positive
cells and dead cells, respectively. To establish a collection gate and exclude cells debris,
non-transfected cells, used as control samples, were displayed on a forward scatter (FSC) vs.
side scatter (SSC) dot plot. Positive transfection control samples containing Lipofectamine™
2000 transfected cells were used to establish cytometer settings and channel compensations.
Cell viability data were normalized in relation to the value of non-transfected control
cells. For each sample, 10,000 events were collected. The experiments were carried out in
triplicate for each condition.
2.13. Statistical Analysis
The statistical analysis was carried out using the IBM SPSS Statistics 25 software. The
Shapiro–Wilk test was used to evaluate normal distribution, and the Levene test was used
to evaluate homogeneity of variance. In parametric conditions, Student´s t test or ANOVA
followed by the post-hoc HSD Tukey test was performed. In non-parametric conditions,
the Kruskal–Wallis test and/or the Mann–Whitney U test for unpaired comparisons was
performed. In all cases, p value ≤ 0.05 was considered statistically significant. Data were
represented as mean ± standard deviation (SD).
3. Results
3.1. Characterization of the Thermostability of Niosomes
The thermostability of niosome formulations 1, 2 and 3 was evaluated by differen-
tial scanning calorimetry. As shown in Figure 2, the thermogram of formulation 1 (blue
line) was slightly shifted to the right compared to formulations 2 (red line) and 3 (grey
line), indicating higher thermal stability than its counterparts (Figure 2A). Regarding their
thermal melting temperatures (Tm), formulation 1 showed five well-defined peaks, while
in the case of formulation 2 a first wide and weak peak around 15 ◦C followed by four
well-defined peaks were obtained. In the case of formulation 3 only two clear peaks
were reported (Figure 2B). Remarkably, although slightly shifted to the right, formula-
tion 1 coincided with formulation 3 in Tm1 and with formulation 2 in Tm2, Tm3, Tm4
and Tm5 (Figure 2A,B).
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Figure 2. (A) Thermograms of niosomes based on formulations 1 (blue line), 2 (red line) and 3 (grey line) in aqueous
solution. Scan rate: 1.0 ◦C/1 min. (B) Thermal melting temperature (Tm) data for the transitions of niosome formulations.
3.2. Rheological Properties of Niosomes
Rheological studies were performed in order to analyze the viscosity of niosomes
based on formulations 1, 2 and 3 as a function of the shear rate (Figure 3). Formulation 1
(blue line, triangles) showed the lowest viscosity values among the three formulations,
and they remained quite stable when increasing the shear rate, indicating a Newtonian
rheological behavior. On the contrary, formulations 2 (red line, squares) and 3 (grey line,
dots) showed the higher initial viscosity values which declined when incrementing the
shear rate, denoting a pseudoplastic rheological behavior. Regarding the rheological
properties of the non-ionic surfactants employed in niosome formulations, poloxamer
188 (violet line), used to elaborate formulation 2, showed higher viscosity values than
poloxamer 407 (green line), used to elaborate formulations 1 and 3.
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Figure 3. Rheology measurements. Main graph: viscosity curves of niosomes based on formulations
1 (blue line, triangles), 2 (red line, squares) and 3 (grey line, dots) expressed as a function of shear rate.
Secondary graph: viscosity curves of poloxamer 188 (violet line, inverted triangles) and poloxamer
407 (green line, rhombus) expressed as a function of shear rate.
3.3. Morphology, Size, Dispersity and Superficial Charge
Niosome formulations 1, 2 and 3 showed a clear spherical shape without particle
aggregation (Figure 4A). The mean particle size of niosome formulations 1, 2 and 3 were
114.43 ± 0.64 nm, 110.40 ± 0.40 nm and 191.73 ± 4.11 nm, respectively (Figure 4B, bars).
When complexing to pEGFP at the cationic lipid/DNA mass ratio 2/1, nioplexes based
on formulation 1 showed a 2-fold increase in mean particle size, while nioplexes based
on formulation 2 presented a more restrained increase of around 1.5-fold and nioplexes
based on formulation 3 did not present a significant increase. When increasing the cationic
lipid/DNA mass ratios to 5/1 and 10/1, mean particle sizes declined progressively, with a
more pronounced slope in the case of nioplexes based on formulations 2 and 3. In all cases,
the mean size values of nioplexes based on formulation 1 were higher than the values
based on formulations 2 and 3. Zeta potential data of niosome formulations 1, 2 and 3 were
+31.37 ± 4.78 mV, +39.93 ± 2.64 mV and +34.63 ± 5.28 mV, respectively (Figure 4B, dots).
After the addition of DNA, an initial decrease was observed at the cationic lipid/DNA
mass ratio 2/1 and then values increased again with increasing cationic lipid/DNA ratios
without reaching the original zeta potential of niosomes in all cases. Regarding dispersity
(Ð), formulations 1 and 2 showed low values below 0.35, while formulation 3 had higher
values both with and without DNA (Figure 4C).
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Figure 4. Characterization of niosomes based on formulations 1, 2 and 3 and their corresponding nioplexes vectoring
EGFP plasmid (pEGFP) at cationic lipid/DNA mass ratios 2/1, 5/1 and 10/1. (A) Transmission electron microscopy (TEM)
images. Scale bar: 200 nm. (B) Mean particle intensity (bars) and zeta potential (symbols) values of niosomes and their
corresponding nioplexes represented by the mean ± SD of three measurements. (C) Dispersity (Ð) values of niosomes and
their corresponding nioplexes. Each value represents the mean ± standard deviation (SD) of three measurements.
3.4. Nioplexes Membrane Packing Studies
Membrane GP values were determined in niosomes based on formulations 1, 2 and 3
their corresponding nioplexes. As shown in Figure 5, formulation 1 niosomes showed
negative GP value close to zero that increased at 2/1 and 5/1 cationic lipid/DNA mass
ratio to values near 0.7 and 0.5, respectively. Such values decreased again to values around
zero at 10/1 mass ratio values. Formulation 2 followed a similar pattern, with the lowest
negative value in niosome formulation and, with higher, positive values at ratios 2/1 and
5/1 and a pronounced decrease to values near zero at the cationic lipid/DNA mass ratio
10/1. Formulation 3 presented an intermediate negative value in the niosome formulation
and the lowest GP values near zero that switched to negative values at cationic lipid/DNA
mass ratios 2/1, 5/1 and 10/1.
3.5. Evaluation of Niosome-pEGFP Interactions by ITC
The interactions between DNA and niosome formulations 1, 2 and 3 were followed
by ITC, and the heat evolved per gram of DTPA injected as a function of the cationic
lipid/DNA mass ratio is shown in Figure 6. Results showed that the titration profiles
of niosomes 1 and 2 followed a similar trend, while a clear change was observed in the
titration profile of formulation 3, lacking chloroquine.
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Figure 5. Laurdan general polarization (GP) values measured of niosomes based on formulations 1, 2 and 3 and their
corresponding nioplexes at cationic lipid/DNA mass ratios 2/1, 5/1 and 10/1.
Figure 6. Isothermal titration calorimetry (ITC) of (A) formulation 1 (1:1 dilution), (B) formulation 2 and (C) formulation 3
into pEGFP. Upper panels show the raw data for the injection of respective formula into the plasmid solution (black line) or
the blank solution (blue line). Lower panels show the dependence of the heat evolved by gram of cationic lipid injected as a
function of the DTPA/pEGFP mass ratio in the sample cell (measures were carried out at 25 ◦C).
3.6. Buffer Capacity and Endosomal Escape of Nioplexes
In order to determine the ability to escape from intracellular endosomes, the buffer
capacity and the DNA release profile from artificial endosomes of nioplexes based on for-
mulations 1, 2 and 3 were evaluated. Among the three niosomes, no significant differences
were observed between formulations 1 (blue line, triangles) and 2 (red line, squares), while
formulation 3 (grey line, dots) showed the lowest buffering capacity (Figure 7A). Regarding
the ability of formulations to escape from endosomal compartment analogues based on PS,
results showed that formulations released the DNA after the contact with the lipid membrane
of the PS micelles, especially formulation 1, which revealed the highest ability to escape from
artificial endosomes at all cationic lipid/DNA mass ratios evaluated (Figure 7B).
Pharmaceutics 2021, 13, 1787 12 of 22
Figure 7. Buffer capacity and endosomal escape evaluation. (A) Analysis of pH buffering capacity of niosomes based on
formulations 1 (blue line, triangles), 2 (red line, squares) and 3 (grey line, dots). (B) DNA release profiles in agarose gel
electrophoresis assay of nioplexes based on niosome formulations 1, 2 and 3 at cationic lipid/DNA mass ratios at 2/1, 5/1
and 10/1 from phosphatidylserine (PS) micelles. OC: open circular. SC: supercoiled.
3.7. Cell Viability and Transfection Efficiency of Nioplexes
Transfection and cell viability assays were performed during 7 days in CuFi-1 cells
with nioplexes based on formulations 1, 2 and 3 vectoring pEGFP at cationic lipid/DNA
mass ratios 2/1, 5/1 and 10/1. Although the highest ratio 10/1 sometimes achieved higher
transfection efficiency, the best results in terms of desirable balance between efficiency and
cell viability were obtained with the intermediate mass ratio 5/1 (Figure S1). Focusing on
the cationic lipid/DNA mass ratio 5/1, formulations 1 and 2 showed similar fluorescence
intensity values, and both reached the maximum fluorescence peak 72 h after transfection
(Figure 8A, blue and red lines, respectively). After 72 h, the fluorescence intensity values
declined slightly, but were relatively stable until the 7th day. Formulation 3 revealed lower
fluorescence intensity values than its counterparts all over the 7 days of the experiment,
and reached its maximum value 48 h after transfection (Figure 8A, grey line). Figure 8B
shows representative images of CuFi-1 cells transfected with nioplexes 1, 2 and 3 at the
cationic lipid/DNA mass ratio 5/1 over time, with no or little transfection at 4 h and
evident increase of EGFP positive cells from 24 h after transfection. Differences on the
amount of EGFP positive cells between cells exposed to formulations 1 or 2 and to for-
mulation 3 are also visible in these images. Finally, in order to quantify more precisely
the differences in transfection efficiency and cell viability between nioplexes based on
formulations 1 and 2, further flow cytometry assays were conducted. Results showed that,
at cationic lipid/DNA mass ratios 5/1 and 10/1, the percentage of EGFP expressing cells
was significantly (p ≤ 0.05) higher with nioplexes based on formulation 1 (21.02 ± 2.68%
and 28.22 ± 0.76%, respectively) than with those based on formulation 2 (13.94 ± 0.56%
and 20.75 ± 1.68%, respectively) (Figure 8C, bars). Regarding cell viability, formulation 1
also showed significantly (p ≤ 0.05) higher percentages of live cells than formulation 2,
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although in both cases values decreased when increasing the cationic lipid/DNA mass
ratios (Figure 8C, dots). These results were further confirmed by the MFI values, where at
cationic lipid/DNA mass ratios 5/1 and 10/1, formulation 1 also showed higher values
than formulation 2 with significant differences (values around 400 vs. values around 300,
respectively) (Figure 8D). Lipofectamine™ 2000 was used as a transfection positive control
and showed 34.07 ± 2.52% of EGFP expressing live cells, 65.36 ± 1.29% of cell viability and
a MFI value of 626.34 ± 26.30 (data not shown).
Figure 8. Cont.
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Figure 8. Transfection capacity and cell viability assays. (A) Fluorescence intensity over time in CuFi-1 cells transfected
with nioplexes based on formulation 1, 2 and 3 at cationic lipid/DNA mass ratio 5/1. Each value represents the mean ± SD
of three measurements. (B) Fluorescence microscope images showing EGFP positive CuFi-1 cells transfected with nioplexes
based on formulation 1, 2 and 3 at cationic lipid/DNA mass ratio 5/1 and cellular appearance over time. (C) Percentages of
EGFP positive live cells (bars) and cell viability (symbols) measured by flow cytometry in CuFi-1 cells 48 h after transfection
with nioplexes 1 and 2 at cationic lipid/DNA mass ratios 2/1, 5/1 and 10/1. Each value represents the mean ± SD of
three measurements. (D) Mean fluorescence intensity values. Each value represents the mean ± SD of three measurements.
Statistical significance: * p ≤ 0.05 in transfection and MFI; # p ≤ 0.05 in cell viability.
4. Discussion
In this work we determined, on the one hand, the influence of incorporating chloro-
quine and, on the other hand, the effect of varying non-ionic surfactant components and
their phase of addition—aqueous or organic—on the biophysical performance of niosome
formulations 1, 2 and 3. As it is well known by scientific community, chloroquine is a
chemical compound that can promote the endosomal escape and enhance the transfec-
tion efficiency [42]. However, as far as we are concerned, how chloroquine affects the
biophysical performance and correlate with their transfection efficiency of niosome formu-
lations has not been assessed until now. It has also been well described that variations on
chemical structure and composition, biophysical properties and preparation methods of
lipid-based non-viral vectors can affect to their gene delivery efficiency and cytotoxicity
both in vitro and in vivo [43]. In this respect, some works have described how liposomal
formulations with different manufacturing process carrying amphotericin B resulted in sig-
nificant differences in terms of physicochemical properties, efficiency and toxicity, despite
the fact of presenting the same components in their formulations [44–46]. Additionally,
the manufacturing processes required for the scale-up production of such formulations
in order to reach clinical practice could also affect to their biological performance. To
avoid this scenario, the European Medicines Agency (EMA) and the Food and Drug Ad-
ministration (FDA) specified the requirements required to obtain the bioequivalence of
liposomal formulations [47] and compiled precise guidance documents for the complete
characterization of nanosystems in order to guarantee the safety and efficacy of the new
drugs based on nanomaterials [48,49]. All these requirements could also be applied to
niosome formulations in order to track the manufacturing process as well as to evaluate
their properties and activity, considering that they could represent an attractive alternative
to liposomes with better properties for gene therapy purposes.
Regarding the chemical structure and composition of the niosome formulations 1, 2
and 3 developed in the present work, the compounds used have been previously reported
for nucleic acid delivery. In particular, the cationic lipid DTPA, which contains two sat-
urated hydrocarbonated chains, a glycerol backbone and an amino as cationic head [18],
has shown suitable properties for gene therapy [18,41,50,51]. As non-ionic surfactants
polysorbate 80 and poloxamer 188 and 407 were included. Polysorbate 80 is one of the
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most employed non-ionic surfactant in niosomes because avoids nanoparticle aggregation,
decreases the toxicity frequently associated to cationic lipids and improves the transfec-
tion efficiency due to its polyethylene glycol (PEG) chains [7,50,52]. Poloxamer 188 can
prevent and repair membrane disruption and is useful to stabilize the lipid bilayer of
niosomes [53–55], thereby improving the gene transfer efficiency [56]. Poloxamer 407 has
been used in micro- and nanoparticles to stabilize and prolong the half-life of formulations
as well as to prevent from aggregation [57,58] and to enhance the transfection process [59].
Regarding the HLB values of these non-ionic surfactants, poloxamer 188 (HLB = 28) has
the highest value, followed by poloxamer 407 (HLB = 18–22) and, lastly, by polysorbate
80 (HLB = 15). Nevertheless, because of their amphiphilic nature, all of them could be
incorporated either in the aqueous or in the organic phase during the preparation of na-
noemulsions [39]. As “helper” component, formulations 1 and 2 included chloroquine due
to its capacity to protect and interact with the DNA [60,61]. Moreover, chloroquine improves
the endosomal escape impairing the fusion of endosomes and lysosomes because of its proto-
nation inside the vesicles, causing a higher pH value that avoids the enzymatic lysosomal
activity [30,62–65]. Therefore, in the present work, we hypothesized that chloroquine would
not only act as a “helper” component, but also as a biophysical performance enhancer agent
inside the niosomes. For this purpose, an exhaustive biophysical characterization is described
in order to stablish its potential correlation with their biological activity.
First, niosome formulations 1, 2 and 3 were prepared by the o/w emulsion technique
and analyzed by DSC in order to determine their thermal stability and associated structural
transitions. The Tm analysis, which corresponds to the maximum peak of endothermal
events [66], showed relevant differences among the three formulations. Such differences
are commonly found in lipid nanoparticle dispersions with various components affecting
molecular packing, which is reflected in the different melting points and enthalpies [67].
The “fine structure” of the thermogram in the region between 48 ◦C and 70 ◦C of formula-
tions 1 and 2 is clearly associated with the effect caused by the chloroquine component on
the disposition of lipids within the niosome. This effect could be related, on the one hand,
to the higher packing shown by the lipids in both formulations and, on the other hand,
to their higher transfection efficiency. The removal of chloroquine from formulation 3
caused disappearance of the well-defined transitions observed in that region and, instead,
a possible transition between 40 ◦C and 50 ◦C was observed. On the other hand, the shift
towards higher temperatures observed in formulation 1 could be due not only to the chloro-
quine content (formulation 1 vs. formulation 3), but also to the substitution of poloxamer
(188 in formulation 2, by 407 in formulation 1), and the incorporation of such surfactants in
the organic phase (formulation 1) instead of in the aqueous phase (formulation 2). This
could be related to its ability to stabilize the formulations, meaning that higher temper-
atures are needed in order to induce structural alterations in formulation 1 compared to
its counterparts as indicated by the noticeable shift to the right of its thermogram [68]. In
addition, the transition centered at 21.76 ◦C (formulation 3) or 24.47 ◦C (formulation 1)
is possibly associated with the presence of poloxamer 407, since in formulation 2 a wide
and low intensity transition is observed instead, which was centered around 15–16 ◦C and
which could be due to the presence of poloxamer 188.
Next, rheological studies were conducted in order to evaluate the flow behavior of
the niosome formulations. Formulation 2 appeared to be the most viscous among the
three formulations, with values that clearly declined when increasing the shear rate, as it is
common in solutions with a pseudoplastic rheological behavior [69]. Formulation 3 showed
a similar pseudoplastic behavior, with lower viscosity values. Interestingly, formulation 1
showed the lowest and more constant viscosity values, which would indicate a Newtonian
rheological behavior [69]. In this regard, the major viscosity values of formulation 2 could
be in part attributed to its non-ionic surfactant poloxamer 188, which has higher viscosity
values than poloxamer 407 used in the preparation of formulations 1 and 3. Therefore, these
results suggested that the substitution of poloxamer 407 by poloxamer 188 and, probably,
also its incorporation in the aqueous phase instead of the organic phase, increased the
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viscosity and affected to the rheological behavior of the formulation. On the other hand,
the differences found between formulations 1 and 3 could only be due to the presence
of chloroquine, as it is the only difference between both formulations. In this sense, the
incorporation of chloroquine in formulation 1 significantly affects the arrangement of the
lipid membrane, as evidenced by DSC studies and GP values (see below), modifying its
rheological behavior. Taken together, rheological analysis suggests that the low viscosity
value of formulation 1 could contribute, among many other physicochemical factors, to the
highest transfection efficiency reported by this formulation. Such viscosity values would
maintain constant at different shear stress due to the Newtonian rheological behavior [70].
Subsequently, in order to further understand the differences between the three for-
mulations and their applicability for gene delivery purposes, niosomes 1, 2 and 3 were
complexed to the reporter pEGFP at cationic lipid/DNA mass ratios 2/1, 5/1 and 10/1 to
obtain their corresponding nioplexes. Their morphology, size, dispersity and zeta potential
were studied, parameters that provide insights about the transfection capacity of the for-
mulations. The size of all niosomes and nioplexes ranged between 100 and 230 nm, which
it is appropriate to enhance the cellular uptake of the nanoparticles [71]. The positive zeta
potential values of the three niosomes enhance electrostatic interactions with the plasmid
DNA and, therefore, the nioplexes formation [72]. Additionally, these high positive val-
ues prevent particle aggregation and improve cellular internalization [73]. As predicted,
surface charge data decreased after the addition of the genetic material due to the partial
neutralization of positive charges of the cationic lipid amine groups by the negatively
charged phosphate groups of the DNA [74]. Regarding dispersity, formulations 1 and 2
revealed narrow size distributions, as indicated by their low values, while formulation 3
showed higher values, indicating a more heterogeneous particle size distribution than its
counterparts [7], which could be due to the lack of chloroquine.
The biophysical properties studied are closely related to another relevant parameter,
specifically, to the niosome membrane packing. Therefore, we studied the membrane envi-
ronment in niosome formulations 1, 2 and 3 and their corresponding nioplexes vectoring
pEGFP at cationic lipid/DNA mass ratios of 2/1, 5/1 and 10/1, by measuring the GP
values. In niosomes measurements, the highest value was obtained by formulation 1
and the lowest by formulation 2. The nioplexes values showed clear differences of for-
mulations 1 and 2 respect to formulation 3, especially at cationic lipid/DNA mass ratios
of 2/1 and 5/1. Results revealed a more disordered membrane lipid packing profile in
formulation 3 compared to formulations 1 and 2 after complexing with pEGFP, which
showed GP values similar to the lipid packing values found in model membrane [75]. The
highest membrane lipid packing profile was obtained by nioplexes based on formulations
1 and 2 with chloroquine content, yielding more condensed complexes than formulation 3,
devoid of chloroquine. In addition, the increase obtained in GP values from niosomes to
nioplexes based in formulation 1 and 2, could indicate that some ordered packing was
formed via interaction of pDNA with the niosomes components, suggesting a relevant role
of chloroquine in the packing of nioplexes possibly due to its ability to interact with the
DNA [60,61]. Moreover, slight variations between formulations 1 and 2 could be attributed
to the different poloxamer non-ionic surfactants content, since poloxamer 407—used to
prepare formulation 1–, presents longer alkyl chains than poloxamer 188—used to prepare
formulation 2–, which is often related to higher rigidity and, therefore, could contribute to
increase the membrane packing of nioplexes based on formulation 1. As indicated above,
membrane packing is also related with other biophysical parameters studied in this work,
such as thermal stability, viscosity and the rheological behavior of the formulations which,
all together, could affect to the gene delivery process. In fact, it has been described that the
presence of the drug astaxanthin in liposomes affects to the thermodynamic, viscoelastic
and electrical properties of lipid membranes [76]. In our case, it could be assumed that
the incorporation of chloroquine in the niosome formulation increases the membrane
lipid packing of nioplexes as well as the thermal stability of formulations and, ultimately,
enhances the transfection efficiency of these niosome formulations.
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The effect of chloroquine incorporation in the interaction of niosome formulations with
DNA was further supported by ITC results. Titration of niosome formulations into DNA
showed that formulations 1 and 2 reached to a plateau or saturation point at DTPA/pEGFP
mass ratios around 2/1–3/1, whereas saturation with formulation 3 required a mass
ratio of 9/1, which suggests a less binding affinity for DNA molecules. Therefore, it
can be concluded that the addition of chloroquine increased the DNA binding affinity
of niosome formulations, which is in accordance with previous reports [4] and would
also in part explain the higher transfection efficiency of these formulations compared to
formulation 3. Additionally, ITC results suggested that variations reported in the structural
and functional properties of nioplexes based in formulations 1 and 2 at mass ratios above
2/1 likely reflect a redistribution of DNA leading to nioplexes with a decreasing fraction
of plasmid molecules bound as niosome concentration was further increased. Besides,
the titration results were in accordance with the results obtained from nioplexes packing
since the presence of chloroquine promoted greater order of niosome membrane packing.
Once characterized the capacity to bind DNA, agarose gel electrophoresis assays were
performed to evaluate the ability to protect and release the genetic material from enzymatic
degradation (Figure S2). Results showed that the three formulations were able to protect
the genetic material against enzymatic degradation at cationic lipid/DNA mass ratios 5/1
and 10/1, but not at the lower mass ratio 2/1, suggesting that this ratio would not be
suitable for gene delivery purposes. For subsequent cell transfection assays, we selected
the cationic lipid/DNA mass ratio 5/1 in all formulations, because it reported enough
capacity to protect the genetic material and contributed more than the higher ratio 10/1 to
mitigate the cytotoxic effect sometimes associated to high amounts of cationic lipids [77].
The last parameters that were evaluated before moving on to biological assays were
the buffer capacity and the endosomal escape ability from artificial PS micelles (mimicking
cellular endosomes) of the niosome formulations. Considering that DNA quantity loaded
in all wells was the same, the differences observed in the percentages of released DNA from
nioplexes could be explained by the different chemical composition of the formulations.
Among the three niosomes, formulation 3 showed the lowest buffering capacity and the
lowest ability to escape from artificial endosomes. This suggests that the incorporation of
chloroquine in formulations 1 and 2 might enhance the endosomal escape via the proton
sponge effect, which is a widely used strategy in formulations with a high buffering capacity,
as is the case of these two formulations [14,30]. However, other possible endosomal escape
mechanisms such as pore formation in the endosomal membrane, flip-flop mechanisms or
fusion in the endosomal membrane mechanisms, among others, could also contribute to
the endosomal escape behavior observed [78–80]. The ability to release the DNA once the
formulations contact the lipid membrane of the endosomal compartment is essential for an
efficient transfection process [41].
Finally, the biological performance of nioplexes 1, 2 and 3 at cationic lipid/DNA
mass ratio 5/1 was studied in CuFi-1 cells, because of the autosomal monogenic recessive
condition of cystic fibrosis disease, which makes it particularly attractive for future gene
therapy applications using niosomes as non-viral vectors [81]. In particular, the cell viability
after exposure to nioplexes, the transfection efficiency of the formulations and the duration
of gene expression were evaluated. Results clearly showed that the presence of chloroquine
was necessary to achieve high transfection levels and, in addition, formulations with this
component were well tolerated by the cells as indicated by the healthy cellular appearance
along 7 days in cells exposed to formulations 1 and 2. Generally, chloroquine is considered
to be cytotoxic at concentrations superior to 100 µM, while it has been reported to enhance
endosomal escape of polymeric nanoparticles at a concentration of 75 µM [82]. However,
in this work cells were exposed to a concentration of chloroquine of 24.23 µM, which
was enough to enhance endosomal escape and far away from the cytotoxic concentration.
Considering that most niosome formulations enter the cells via endocytic pathways, which
usually end in late endosomes, the ability to promote endosomal escape is essential in order
to reach high transfection efficiencies [7]. Therefore, the endosomal escape observed in
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formulations 1 and 2 would in part explain the higher transfection efficiency of chloroquine-
containing niosomes compared to formulation 3, devoid of chloroquine.
Regarding the duration of gene expression, the fluorescence intensity values reached
their maximum 48–72 h after transfection and then were maintained quite stable or de-
clined slightly over time. Interestingly, the gene expression was maintained over seven
days, which affects to the design of specific dosage regimens for gene therapy applications.
Hence, the kinetics evaluation of transgene expression employing formulations 1, 2 and
3, corroborated the key role of chloroquine in this process. In order to further analyze
the influence of non-ionic surfactants and the inversion of the addition phase on the bi-
ological performance of formulations 1 and 2, additional more accurate flow cytometry
studies were carried out at 48 h post-transfection [7]. Results showed significant better
cell tolerance as well as higher EGFP positive cell percentages and MFI values in cells
treated with formulation 1, revealing this formulation as the best of the three evaluated
for gene delivery purposes. This could be attributed to the specific biophysical advan-
tages shown by formulation 1, including its superior thermal stability and a Newtonian
rheological behavior, as well as to other non-considered parameters such as the cell entry
pathways or the cellular uptake capacity. Therefore, it could be deduced that not only
the chloroquine content, but also the non-ionic surfactant chemical composition and pro-
tocol of incorporation also affects to the transfection efficiency of niosome formulations,
although further research is needed in order to elucidate the exact mechanism of such effect.
Hence, formulation 1, which contains chloroquine in the aqueous phase and surfactants
incorporated in the organic phase, might be an encouraging non-viral strategy for gene
therapy aimed at cystic fibrosis disease. In this regard, previous in vivo studies carried
out by our group showed a successful gene delivery capacity of formulation 1 in central
nervous system [62], but an in depth biophysical study and implementation in congenital
disease model, as cystic fibrosis, was a missing issue.
5. Conclusions
In conclusion, the main findings of the present study are obtained from the com-
parative evaluation, on the one hand, of formulations 1 and 2, which differed on the
composition of non-ionic surfactant and on the phase of addition of those components and,
on the other hand, of formulations 1 and 3, which only differed in the presence or absence
of the helper component chloroquine. Differences observed on formulations 1 and 3 clearly
revealed the importance of chloroquine content in niosome vesicles since affected not
only to physicochemical parameters but also to the biological performance of niosomes.
Overall, results revealed that chloroquine improved thermal stability, lowered viscosity
and reduced particle size and dispersity values. In addition, chloroquine content improved
DNA binding affinity and membrane packing organization in corresponding nioplexes.
Such relevant parameters along with the enhanced buffering capacity could explain, at
least in part, the highest transfection efficiency values reported when chloroquine was
incorporated into the niosome formulations. The increased capacity of such niosomes that
contain chloroquine to escape from artificial endosomes could also contribute to improve
gene delivery efficiency. Thus, chloroquine emerges as an interesting material able to
improve the biophysical properties and the transfection efficiency of niosomes for non-viral
gene therapy applications. On the other hand, the effect of both chemical composition
and protocol of incorporation of non-ionic surfactants (formulation 1 vs. formulation 2),
resulted in subtle biophysical variations, although formulation 1 showed better thermal sta-
bility, lower viscosity values with Newtonian rheological behavior and higher transfection
efficiency. Taken together, these results support the requirements of the regulatory agencies
for the complete characterization of nanoparticles aimed for biomedical applications and
scaling-up. Of note, the biophysical parameters evaluated for full physicochemical and
biological characterization of niosomes and their corresponding nioplexes, could be used as
gold standard for further gene therapy nanosystems evaluation. Hence, the present work
provides an in depth analysis of different biophysical parameters and characterization
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strategies that are relevant for nanosystems in gene delivery purposes and that might be
interesting to include in the specifications of regulatory agencies for the evaluation of new
drugs based on nanomaterials.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/pharmaceutics13111787/s1, Figure S1: Transfection efficiency and cell viability assays in
CuFi-1 cells transfected with nioplexes based on formulation 1 (F1), 2 (F2) and 3 (F3) at cationic
lipid/DNA mass ratios 2/1, 5/1 and 10/1. Figure S2: Protection and SDS-induced release of DNA in
niosome formulations 1, 2 and 3 complexed to pEGFP at cationic lipid/DNA mass ratios 2/1, 5/1
and 10/1 visualized by agarose gel electrophoresis.
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